p
e
p
e
pharmacokinet
toxic
nasal
cilia
immunomodul
effect
spraguedawley
rat
follow
intranas
deliveri
thymopentin
without
absorpt
enhanc
peptid
polypeptid
play
critic
role
immun
system
shown
promis
immunomodul
properti
thymopentin
tp
synthet
pentapeptid
arglysaspvaltyr
repres
fragment
natur
occur
amino
acid
thymopoietin
tmpo
reproduc
biolog
activ
thymopoietin
influenc
immun
system
promot
differenti
thymocyt
affect
function
matur
tcell
use
immunomodul
agent
treatment
rheumatoid
arthriti
acquir
immunodefici
syndrom
aid
sever
acut
respiratori
syndrom
sar
cutan
tcell
lymphoma
cancer
immunodefici
primari
immunodefici
thymopentin
mainli
administ
intramuscularli
present
clinic
therapi
altern
parenter
thymopentin
nasal
deliveri
pharmacokinet
toxic
nasal
cilia
immunomodul
effect
tlymphocyt
subset
b
r
c
thymopentin
tp
synthet
pentapeptid
use
clinic
modul
immnuodefici
intramuscular
administr
object
studi
investig
pharmacokinet
use
normal
rat
toxic
nasal
cilia
well
immunomodul
effect
use
immunosuppress
rat
intranas
deliveri
thymopentin
without
absorpt
enhanc
absorpt
extent
fluorescein
isothiocyan
fitc
label
tp
via
nasal
deliveri
singl
dose
significantli
improv
incorpor
sodium
deoxychol
brij
chitosan
respect
fitctp
also
absorb
extent
rang
intranas
administr
fitctp
alon
fitctp
sodium
capryl
bacitracin
respect
seven
consecut
day
multipl
dose
tp
formul
sodium
deoxychol
brij
caus
appar
injuri
nasal
cilia
indic
two
enhanc
would
appropri
nasal
deliveri
result
superoxid
dismutas
activ
maleic
dialdehyd
tlymphocyt
subset
ratio
analys
suggest
select
enhanc
improv
modul
effect
tp
immunosuppress
rat
overal
evalu
intranas
tp
alon
tp
chitosan
tp
bacitracin
formul
may
suitabl
futur
clinic
applic
elsevi
inc
right
reserv
applic
patientfriendli
deliveri
activ
peptid
mucos
rout
entri
major
interest
peror
dose
common
rout
applic
system
deliveri
drug
limit
peptid
due
extens
metabol
poor
mucos
permeabl
nasal
drug
deliveri
propos
feasibl
altern
parenter
inject
due
high
permeabl
nasal
epithelium
avoid
firstpass
metabol
conveni
administr
rout
number
peptid
protein
drug
restrict
oral
administr
intens
investig
system
medic
nasal
administr
howev
nasal
tp
deliveri
potenti
use
administr
rout
report
accord
knowledg
gener
polypeptid
unabl
overcom
mucos
barrier
andor
degrad
reach
blood
stream
nasal
deliveri
tp
may
encount
situat
although
molecular
weight
tp
w
rel
low
among
approach
explor
far
order
optim
transport
peptid
molecul
across
mucos
barrier
use
penetr
enhanc
mucos
enzym
inhibitor
repres
challeng
promis
strategi
therefor
sever
tp
prepar
intranas
administr
formul
incorpor
five
absorpt
enhanc
includ
sodium
deoxychol
sdch
sodium
carpryl
sca
polyoxyethylen
lauryl
ether
brij
chitosan
bacitracin
respect
furthermor
tp
solut
administ
intraven
intranas
evalu
effect
nasal
deliveri
object
studi
investig
pharmacokinet
toxic
nasal
cilia
immunomodul
effect
spraguedawley
rat
intranas
administr
thymopentin
without
absorpt
enhanc
materi
method
spraguedawley
rat
weigh
g
obtain
experiment
anim
center
peke
univers
maintain
lightdark
cycl
anim
allow
free
access
standard
rat
chow
water
temperatur
rel
humid
maintain
respect
rat
acclimat
day
prior
experi
care
handl
anim
perform
approv
institut
author
laboratori
anim
care
peke
univers
chitosan
dispers
deioniz
water
phosphor
acid
ad
system
agit
chitosan
dissolv
complet
final
concentr
chitosan
wv
ph
sdch
wv
sca
wv
brij
wv
bacitracin
wv
dissolv
ph
phosphat
buffer
solut
pb
consist
mmoll
potassium
dihydrogen
phosphat
mmoll
sodium
hydroxid
respect
solut
use
stock
solut
absorpt
enhanc
fitctp
dissolv
stock
solut
prepar
sampl
nasal
administr
pharmacokinet
studi
respect
addit
fitctp
directli
dissolv
pb
ph
solut
intraven
inject
nasal
administr
control
respect
similarli
unlabel
tp
pharmacodynam
studi
prepar
procedur
nasal
administr
tp
perform
earlier
report
briefli
normal
male
spraguedawley
rat
equal
divid
eight
group
five
fast
h
prior
experi
respect
rat
anesthet
intraperiton
inject
urethan
gkg
restrain
supin
posit
rat
tracheotomis
divert
airflow
nasal
passag
aid
breath
esophagu
close
ligat
onto
tracheal
cannula
rat
group
given
ml
fitctp
pb
solut
tail
vein
inject
singl
dose
mgkg
group
ii
ml
fitctp
pb
solut
intranas
administr
singl
dose
mgkg
rat
group
iii
group
viii
administ
intranas
ml
fitctp
solut
contain
sdch
wv
sca
wv
brij
wv
chitosan
wv
bacitracin
wv
chitosan
wv
combin
bacitracin
wv
singl
dose
mgkg
respect
intranas
administr
fitctp
solut
care
inject
nasal
caviti
use
microlit
syring
blunt
needl
experi
visibl
leak
solut
observ
administr
site
administr
volum
ml
blood
sampl
drawn
min
orbit
venou
plexu
rat
respect
blood
sampl
immedi
put
heparin
tube
store
min
centrifug
revolut
per
minut
min
room
temperatur
plasma
collect
store
analysi
volum
ml
plasma
dilut
pb
solut
fitctp
plasma
concentr
measur
use
varian
cari
eclips
fluoresc
spectrophotomet
palo
alto
ca
usa
determin
condit
follow
excit
wavelength
nm
emiss
wavelength
nm
slit
excit
nm
slit
emiss
nm
lower
limit
quantit
loq
assay
ngml
linear
obtain
fitctp
concentr
mgml
r
coeffici
variat
interday
intraday
precis
qualiti
control
sampl
rang
accuraci
rang
toxic
nasal
cilia
pharmacodynam
rat
immunosuppress
model
modifi
accord
previou
report
briefli
normal
femal
spraguedawley
rat
equal
divid
nine
group
five
fast
h
prior
experi
rat
group
given
intranas
ml
physiolog
salin
daili
day
normal
control
cyclophosphamid
solut
administ
intraperiton
rat
group
group
dose
mgkg
daili
three
consecut
day
construct
immunosuppress
rat
fourth
day
rat
group
given
intranas
ml
physiolog
salin
daili
day
immunosuppress
control
rat
group
given
ml
tp
solut
tail
vein
inject
dose
mgkg
daili
seven
consecut
day
group
group
administ
intranas
ml
tp
solut
alon
tp
solut
contain
sdch
wv
sca
wv
brij
wv
chitosan
wv
bacitracin
wv
dose
mgkg
daili
seven
consecut
day
respect
day
bodi
weight
rat
weigh
volum
ml
blood
sampl
taken
orbit
venou
plexu
rat
put
anticoagul
tube
tlymphocyt
subset
analysi
use
flow
cytometri
describ
anoth
ml
blood
taken
way
immedi
centrifug
revolut
per
minut
min
plasma
collect
store
assay
sod
activ
mda
content
blood
sampl
rat
sacrif
nasal
septum
mucosa
remov
morpholog
examin
accord
report
spleen
thymu
rat
remov
immedi
wash
use
physiolog
salin
wipe
use
filter
paper
weigh
assess
chang
immun
organ
nasal
septum
mucosa
wash
cold
salin
fix
glutaraldehyd
solut
osmic
acid
sampl
dehydr
seri
concentr
ethanol
replac
namyl
acet
dri
critic
pointer
carbon
dioxid
coat
gold
ion
coater
process
nasal
mucosa
examin
scan
electron
microscop
lv
jeol
japan
superoxid
dismutas
sod
activ
plasma
measur
accord
sod
kit
instruct
test
principl
follow
superoxid
anion
gener
xanthin
oxidas
xod
system
oxid
hydroxylamin
form
product
nitrit
product
stain
kit
reagent
therebi
show
purpl
color
absorb
stain
solut
assay
nm
use
spectrophotomet
shanghai
china
sod
present
sampl
superoxid
anion
concentr
lower
specif
inhibit
thu
lower
colorimetr
signal
consequ
sod
activ
obtain
calcul
assay
volum
ml
plasma
sampl
use
process
assay
valid
met
requir
kit
instruct
one
unit
sod
activ
defin
amount
enzym
requir
inhibit
reduct
sod
specifi
condit
plasma
maleic
dialdehyd
mda
level
measur
accord
mda
kit
instruct
assay
principl
follow
maleic
dialdehyd
secondari
product
lipid
peroxid
react
thiobarbitur
acid
tba
acid
medium
give
pink
color
pigment
absorb
pink
color
read
nm
use
spectrophotomet
assay
volum
ml
plasma
sampl
use
valu
express
nanomol
mda
form
per
millilit
plasma
blood
specimen
process
follow
briefli
volum
ml
anticoagul
blood
ml
ml
ml
ad
one
tube
mix
vortex
incub
room
temperatur
min
control
isotypespecif
antibodi
stain
volum
ml
anticoagul
blood
ml
ml
ml
ad
anoth
test
tube
mix
vortex
incub
room
temperatur
min
sampl
incub
light
avoid
volum
ml
hemolysin
ad
control
sampl
tube
respect
control
sampl
tube
incub
room
temperatur
min
red
cell
lyse
complet
two
specimen
centrifug
speed
revolut
per
minut
min
cell
sediment
tube
separ
collect
wash
ml
pb
twice
fix
ml
paraformaldehyd
tlymphocyt
subset
measur
within
h
use
becton
dickinson
facscalibur
flow
cytomet
englewood
nj
usa
cellquest
softwar
acquisit
analysi
forward
light
scatter
fsc
sidelight
scatter
ssc
log
fluoresc
paramet
util
analysi
lymphocyt
gate
set
adjust
forward
side
scatter
p
e
p
e
popul
lymphocyt
clearli
defin
monocyt
dead
cell
popul
draw
gate
encircl
lymphocyt
popul
total
total
event
per
sampl
tube
collect
noncompartment
pharmacokinet
use
calcul
paramet
use
softwar
practic
pharmacokinet
program
compil
chines
associ
mathemat
pharmacolog
beij
china
area
plasma
concentrationtim
curv
auc
calcul
accord
trapezoid
rule
absolut
bioavail
f
calcul
formula
f
auc
h
dose
iv
auc
h
iv
dose
iv
repres
intranas
intraven
respect
max
c
max
mrt
obtain
noncompartment
analys
denot
time
reach
maxim
concentr
maxim
concentr
termin
halflif
mean
resid
time
fitctp
respect
net
increment
bodi
weight
differ
valu
rat
bodi
weight
first
day
end
day
experi
pharmacodynam
studi
thymu
index
spleen
index
calcul
use
follow
formula
thymu
index
rat
w
thymu
w
rat
spleen
index
rat
w
spleen
w
rat
w
thymu
thymu
weight
rat
w
spleen
spleen
weight
rat
w
rat
bodi
weight
rat
end
day
data
present
mean
ae
standard
error
se
oneway
analysi
varianc
anova
use
determin
signific
among
group
post
hoc
test
bonferroni
correct
use
comparison
individu
group
valu
p
consid
signific
mean
plasma
fitctp
concentr
versu
time
profil
follow
intraven
iv
intranas
administr
fitctp
illustr
fig
iv
administr
dose
mgkg
rat
mean
maxim
fitctp
concentr
ae
mgml
concentr
drop
ae
mgml
min
intranas
administr
tp
variou
formul
immunosuppress
rat
dose
mgkg
daili
seven
consecut
day
scan
electron
micrograph
rat
nasal
mucos
cilia
shown
fig
h
neg
control
cilia
orderli
arrang
surfac
mucosa
administr
physiolog
salin
fig
similar
phenomena
observ
group
administr
mgkg
tp
chitosan
fig
mgkg
tp
bacitracin
fig
mgkg
tp
chitosan
plu
bacitracin
fig
mgkg
tp
alon
fig
respect
result
indic
tp
alon
tp
chitosan
bacitracin
affect
mucos
cilia
contrari
cilia
shed
obviou
eros
observ
nasal
mucosa
rat
administr
mgkg
tp
sdch
fig
mgkg
tp
brij
fig
respect
result
suggest
two
enhanc
exhibit
strong
toxic
nasal
mucos
cilia
rat
respect
addit
slight
cilia
eros
found
nasal
mucosa
administr
mgkg
tp
sca
fig
depict
sca
may
slightli
toxic
cilia
consecut
administr
formul
contain
adjuv
contrast
normal
rat
induc
immunosuppress
rat
show
upright
hair
reduc
appetit
slight
diarrhea
diminish
activ
treatment
tp
situat
gradual
improv
intraven
inject
dose
mgkg
intranas
administr
dose
mgkg
tp
variou
formul
seven
consecut
day
net
increment
rat
bodi
weight
thymu
index
spleen
index
immunosuppress
rat
summar
tabl
result
show
net
increment
bodi
weight
valu
immunosuppress
rat
significantli
lower
compar
normal
control
rat
also
thymu
spleen
index
slightli
reduc
respect
iv
administr
tp
variou
formul
day
immunosuppress
rat
net
increment
valu
improv
variou
extent
compar
normal
control
rat
net
increment
valu
treatment
group
significantli
differ
indic
bodi
weight
gain
patholog
rat
gradual
revers
normal
treatment
tp
howev
reduc
thymu
index
spleen
index
obvious
improv
sod
mda
valu
immunosuppress
rat
follow
intraven
iv
inject
dose
mgkg
intranas
administr
dose
mgkg
tp
variou
formul
seven
consecut
day
describ
tabl
result
show
sod
valu
immunosuppress
rat
significantli
lower
mda
valu
markedli
increas
compar
normal
control
rat
respect
indic
immunosuppress
model
stabli
establish
sod
valu
immunosuppres
rat
administr
tp
brij
chitosan
bacitracin
significantli
increas
compar
immunosppress
control
rat
administr
tp
alon
tp
sdch
tp
sca
slightli
increas
mda
level
immunosuppres
rat
administr
tp
variou
formul
reduc
compar
immunosuppres
model
rat
significantli
distinct
normal
control
rat
tlymphocyt
subset
chang
immunosuppress
rat
follow
administr
variou
formul
shown
tabl
result
show
peripher
blood
immunosuppress
rat
tlymphocyt
percentag
significantli
lower
percentag
slight
reduc
compar
normal
control
rat
respect
contrari
ratio
immunosuppress
rat
markedli
increas
indic
tlymphocyt
patholog
rat
significantli
affect
immunosuppress
intraven
administr
tp
dose
mgk
daili
seven
consecut
day
immunosuppress
rat
lower
valu
significantli
increas
compar
untreat
immunosuppress
rat
percentag
revers
valu
normal
control
rat
correspondingli
increas
ratio
immunosuppress
rat
evid
reduc
also
lower
percentag
administr
tp
alon
tp
variou
formul
significantli
increas
compar
immunosuppress
control
rat
respect
valu
significantli
increas
administr
tp
sdch
brij
obvious
increas
normal
valu
normal
valu
administr
tp
alon
tp
sca
chitosan
bacitracin
respect
ratio
lower
administr
tp
sdch
sca
bacitracin
significantli
reduc
administr
tp
alon
tp
brij
chitosan
respect
thymopentin
small
molecul
pentapeptid
stabl
formul
process
vitro
previou
studi
show
pentapeptid
rapidli
degrad
plasma
degrad
vitro
human
lymphocyt
two
main
fragment
tetrapeptid
tp
thymocartin
lysaspvaltyr
tripeptid
tp
thymotrinan
aspvaltyr
degrad
product
shown
exert
similar
immunomodulatori
activ
affect
humor
cellular
respons
pharmacokinet
thymopentin
character
due
difficulti
measur
blood
concentr
use
tp
consequ
fitc
label
tp
use
pharmacokinet
analysi
present
investig
absolut
bioavail
repres
absorpt
extent
drug
pharmacokinet
analysi
indic
three
penetr
enhanc
includ
sodium
deoxychol
sdch
polyoxyethylen
lauryl
ether
brij
chitosan
significantli
improv
absorpt
extent
fitctp
via
nasal
mucosa
sodium
deoxychol
thought
potenti
absorpt
enhanc
drug
deliveri
enhanc
absorpt
fitctp
sodium
deoxychol
may
caus
interact
mechan
bile
sodium
report
abl
disrupt
lipid
bilay
intercal
phospholipid
form
mix
micel
nasal
promot
effect
brij
may
relat
chang
mucos
permeabl
chitosan
cation
polysaccharid
wide
employ
absorpt
enhanc
abil
chitosan
work
absorpt
enhanc
proven
cell
serv
model
intestin
epithelium
well
vitro
experi
nasal
buccal
mucosa
anim
enhanc
drug
absorpt
chitosan
may
deriv
effect
calcium
adher
junction
rather
direct
effect
tight
junction
calcium
ion
essenti
cell
maintain
intercellular
contact
remov
extracellular
calcium
cultur
epitheli
cell
line
vivo
mucosa
may
result
open
tight
junction
prevent
format
new
tight
junction
mechan
may
also
true
fitctp
comparison
two
enhanc
name
sodium
capryl
bacitracin
increas
absorpt
fitctp
extent
well
previou
studi
demonstr
absorpt
promot
effect
sodium
capryl
insulin
part
associ
chelat
abil
calcium
ion
inhibitori
action
leucin
aminopeptidas
activ
present
studi
immunomodul
activ
fitc
label
tp
remain
tp
data
chines
peptid
compani
therefor
increas
absorpt
fitctp
sodium
capryl
may
associ
similar
mechan
bacitracin
proteas
inhibitor
proven
compat
nasal
cilia
incorpor
bacitracin
nasal
formul
may
benefici
absorpt
fitctp
due
inhibit
tp
degrad
proteas
present
result
indic
absorpt
fitctp
slight
increas
compar
blank
control
absenc
enhanc
although
reach
extent
expect
among
five
enhanc
brij
seem
signific
factor
enhanc
absorpt
compar
iv
administr
rout
present
result
indic
mean
resid
time
mrt
fitctp
administr
via
nasal
caviti
significantli
extend
blood
concentr
maintain
higher
level
formul
suggest
nasal
tp
deliveri
may
suitabl
enhanc
efficaci
therebi
suitabl
futur
clinic
therapi
conveni
administr
rout
intranas
deliveri
peptid
may
target
nasalassoci
lymphoid
tissu
nalt
deep
cervic
lymph
node
nalt
drain
lymphat
drainag
local
nasal
mucosa
nalt
drain
cervic
lymph
node
system
lymphat
system
furthermor
peptid
administ
intranas
rapidli
reach
brain
multipl
pathway
consist
olfactori
neuron
extraneuron
olfactori
epitheli
trigemin
nerv
neuron
pathway
previou
investig
show
intranas
administr
interferon
ifn
led
signific
deliveri
throughout
rat
central
nervou
system
cn
cervic
lymph
node
rel
low
deliveri
peripher
organ
therefor
intranas
administ
peptid
thymopentin
like
end
central
nervou
system
good
bad
treat
multipl
sclerosi
ms
intranas
administr
ifn
may
offer
noninvas
approach
produc
benefici
effect
tyrosin
phosphoryl
ifn
receptor
cn
exert
immunomodul
effect
howev
tp
target
nasalassoci
lymphoid
tissu
may
benefici
nasalassoci
lymphoid
tissu
nalt
mucos
induct
site
upper
respiratori
tract
import
develop
mucos
immun
present
studi
measur
fitctp
administr
via
nasal
caviti
like
absorb
pathway
nasalassoci
lymphoid
tissu
nalt
howev
unclear
much
amount
tp
deliv
brain
happen
tp
reach
cn
thu
issu
deserv
investig
addit
enhanc
addit
may
like
damag
nasal
microsurround
especi
longer
applic
case
evalu
possibl
influenc
nasal
mucos
cilia
assess
follow
exposur
tp
formul
nasal
caviti
immunosuppress
rat
day
respect
present
result
indic
sodium
deoxychol
sdch
polyoxyethylen
lauryl
ether
brij
lead
irrevers
injuri
nasal
mucos
cilia
respect
potenti
applic
chitosan
sodium
capryl
sca
bacitracin
seem
safer
improv
net
increment
bodi
weight
rat
indic
efficaci
tp
shown
treat
group
includ
administr
tp
alon
via
nasal
caviti
result
suggest
nasal
deliveri
tp
alon
may
also
effect
spite
lower
bioavail
result
assess
immun
organ
show
reduc
thymu
index
spleen
index
obvious
improv
day
therapi
indic
immunosuppress
caus
cyclophosphamid
durat
recoveri
may
need
longer
time
therapi
use
immun
modul
superoxid
dismutas
sod
catalyz
dismut
superoxid
radic
hydrogen
peroxid
h
element
oxygen
provid
import
defens
toxic
superoxid
radic
anoth
biomark
provid
indic
lipid
peroxid
level
plasma
concentr
maleic
dialdehyd
mda
one
sever
byproduct
lipid
peroxid
process
plasma
immunodefici
patient
sod
activ
significantli
diminish
mda
level
pronouncedli
increas
similarli
present
studi
show
sod
activ
significantli
increas
mda
level
reduc
therapi
indic
nasal
deliveri
effect
use
either
tp
alon
tp
formul
contain
enhanc
interestingli
multipl
dose
tp
formul
bacitracin
efficaci
improv
sod
reduc
mda
signific
although
absolut
bioavail
rel
lower
singl
dose
may
suggest
reduc
proteas
degrad
tp
would
clinic
signific
longer
administr
accord
phenotyp
function
tlymphocyt
least
divid
four
subset
includ
cytotox
cell
c
suppressor
cell
delay
type
hypersensit
cell
dth
inducerhelp
cell
h
contrasuppressor
cell
cs
cell
common
surfac
marker
express
tlymphocyt
express
surfac
h
cell
surfac
c
cell
repres
matur
tlymphocyt
immunolog
suppress
defici
patient
sever
acut
respiratori
syndrom
sar
acquir
immunodefici
syndrom
aid
infect
etc
peripher
blood
valu
diminish
ratio
irregularli
chang
similar
result
obtain
studi
use
immunosuppress
rat
induc
clyclophoshamid
present
result
indic
nasal
tp
deliveri
variou
formul
either
tp
alon
tp
enhanc
effect
improv
diminish
count
therebi
revers
irregular
ratio
normal
valu
view
efficaci
modul
irregular
ratio
administr
tp
alon
tp
brij
tp
chitosan
seem
signific
conclus
absorpt
extent
fitc
label
tp
via
nasal
deliveri
significantli
improv
incorpor
sodium
deoxychol
sdch
brij
chitosan
respect
fitctp
also
absorb
extent
rang
intranas
administr
fitctp
alon
fitctp
sodium
capryl
bacitracin
respect
sodium
deoxychol
brij
caus
appar
injuri
nasal
mucos
cilia
indic
two
enhanc
would
suitabl
nasal
deliveri
pharmacodynam
investig
suggest
tp
formul
without
enhanc
improv
immnuomudul
efficaci
immunosuppress
rat
overal
evalu
intranas
tp
alon
tp
chitosan
tp
bacitracin
formul
may
suitabl
futur
clinic
applic
r
e
f
e
r
e
n
c
e
